162 related articles for article (PubMed ID: 29661778)
1. Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
Hao D; Liu J; Chen M; Li J; Wang L; Li X; Zhao Q; Di LJ
Clin Cancer Res; 2018 Aug; 24(15):3560-3571. PubMed ID: 29661778
[No Abstract] [Full Text] [Related]
2. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
3. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
[TBL] [Abstract][Full Text] [Related]
5. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
[No Abstract] [Full Text] [Related]
6. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
Liu R; Hu R; Zeng Y; Zhang W; Zhou HH
EBioMedicine; 2020 Jan; 51():102602. PubMed ID: 31911269
[TBL] [Abstract][Full Text] [Related]
7. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
8. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.
Li L; Bai H; Yang J; Cao D; Shen K
Oncotarget; 2017 Feb; 8(9):15136-15148. PubMed ID: 28122348
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
[TBL] [Abstract][Full Text] [Related]
12. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
13. Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Shi Z; Zhao Q; Lv B; Qu X; Han X; Wang H; Qiu J; Hua K
Clin Transl Med; 2021 May; 11(5):e399. PubMed ID: 34047476
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
15. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
Jiménez-Sánchez A; Cybulska P; Mager KL; Koplev S; Cast O; Couturier DL; Memon D; Selenica P; Nikolovski I; Mazaheri Y; Bykov Y; Geyer FC; Macintyre G; Gavarró LM; Drews RM; Gill MB; Papanastasiou AD; Sosa RE; Soslow RA; Walther T; Shen R; Chi DS; Park KJ; Hollmann T; Reis-Filho JS; Markowetz F; Beltrao P; Vargas HA; Zamarin D; Brenton JD; Snyder A; Weigelt B; Sala E; Miller ML
Nat Genet; 2020 Jun; 52(6):582-593. PubMed ID: 32483290
[TBL] [Abstract][Full Text] [Related]
16. The impact on high-grade serous ovarian cancer of obesity and lipid metabolism-related gene expression patterns: the underestimated driving force affecting prognosis.
Cuello MA; Kato S; Liberona F
J Cell Mol Med; 2018 Mar; 22(3):1805-1815. PubMed ID: 29266765
[TBL] [Abstract][Full Text] [Related]
17. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
18. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
[TBL] [Abstract][Full Text] [Related]
19. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
20. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
